^
23d
Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer. (PubMed, Nat Commun)
In this preclinical study, an oncolytic reovirus (RC402) is orally administered to induce antitumor immunity...Oral reovirus treatment is most effective when combined with αPD-1(L1) and/or αCTLA-4, leading to complete colon tumor regression and protective immune memory. Collectively, oral reovirus virotherapy is a feasible and effective immunotherapeutic strategy in preclinical studies.
Journal
|
BATF3 (Basic Leucine Zipper ATF-Like Transcription Factor 3)
|
ReoCure (RC402)
8ms
Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy. (PubMed, Sci Rep)
The anti-tumor effects of mono-treatment with reovirus type 3 Dearing strain (RC402 and RP116) and in combination with interleukin (IL)-18/-21-pretreated eNK cells were investigated on BCC lines (5637, HT-1376, and 253J-BV) using intravesical therapy to simulate in vitro model...Notably, combining RP116 with IL-18/-21-pretreated eNK cells displayed effective cytotoxicity against both HT-1376 and 253J-BV cells. Our findings underscore the potential of a combination therapy using reoviruses and NK cells as a promising strategy for treating bladder cancer.
Preclinical • Journal
|
IL18 (Interleukin 18)
|
ReoCure (RC402)
over3years
[VIRTUAL] Orally available oncolytic reovirus, RC402, effectively promotes anti-cancer immunity and synergizes with immune checkpoint blockade in colon cancer (AACR 2021)
Our study demonstrates that orally available oncolytic reovirus, RC402, could induce potent anti-cancer immune responses and effectively suppress colon cancer progression in combination with anti-PD-1 blockade.
Oncolytic virus • Checkpoint inhibition
|
CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
ReoCure (RC402)